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ABSTRACT 
Background/Objectives: In the last decade a strict link between epigenetics and 
metabolism has been demonstrated. Histone deacetylases (HDACs) have emerged as 
key epigenetic regulators involved in metabolic homeostasis in normal and pathologic 
conditions. Here we investigated the effect of the class I HDAC inhibitor MS-275 in a 
model of obesity induced by a high fat diet (HFD). 
Methods: C57BL6/J male mice were fed HFD for 17 weeks and then randomized in 
two groups treated intraperitoneally with vehicle (DMSO) or with the class I selective 
HDAC inhibitor MS-275 every other day for 22 days. Glucose tolerance test and 
measurement of body temperature during cold exposure were performed. Adipose 
tissues and liver were phenotypically characterized through histological analysis. 
Gene and protein expression analysis of brown and white adipose tissues were 
performed. 
Results: MS-275 treated mice showed 10% reduction of body weight, lower adipocyte 
size, and improved glucose tolerance. Inhibition of class I HDAC determined 
reduction of adipocyte size and of fat mass, paralleled by higher expression of adipose 
functionality markers and by increased rate of lipolysis and fatty acid -oxidation.  
MS-275 also promoted thermogenic capacity, related to “browning” of visceral and 
subcutaneous white adipose tissue, showing increased expression of uncoupling 
protein 1. In brown adipose tissue we observed limited effects on gene expression and 
only reduction of brown adipocyte size. 
Conclusions: This study provides evidence that class I HDAC inhibition stimulated 
functionality and oxidative potential of adipose tissue, improving glucose tolerance 
and ameliorating the metabolic profile in diet-induced obese mice. 
 
©    2016 Macmillan Publishers Limited. All rights reserved.
 3 
INTRODUCTION 
The prevalence of obesity increased at a worrisome rate worldwide and is predicted to 
continuously grow in the next two decades. The fast increase in the number of obese 
people is related to a sedentary lifestyle, accompanied by excessive energy intake not 
adequately counteracted by energy expenditure (1). Obesity is characterized by 
excessive accumulation of body fat and it is often associated with insulin resistance 
and the onset of type 2 diabetes (2). It is nowadays established that genetic 
susceptibility plays a fundamental role in the development of this disorder (3), 
however a role of epigenetics in the pathophysiology of metabolic disorders has 
recently emerged (4). Epigenetic modifications include DNA methylation and histone 
post-translational modifications, such as acetylation, methylation, ADP-ribosylation 
and phosphorylation (5). In the context of metabolic diseases a number of evidences 
highlighted the importance of histone acetylation, focusing the attention on the role of 
histone deacetylases (HDACs) (6-8). These enzymes, by deacetylating histones 
compact chromatin making it less accessible to transcriptional activators (9). Gao and 
colleagues demonstrated that sodium butyrate, a short chain fatty acid that inhibits 
class I and class II HDAC activity, improves diet induced obesity and diabetes (10). 
Class II HDACs affect both histone and non-histone proteins and butyrate inhibits 
both main classes of HDACs thus affecting energy metabolism also via HDAC-
independent mechanisms (11, 12); furthermore it has been shown that butyrate acts 
through free fatty acid receptors (FFAR2 and FFAR3) on the release of the intestinal 
factor glucagon-like peptide-1 (Glp1) (13, 14). Therefore, further investigations were 
undertaken to fully understand the role of HDACs in the regulation of energy 
metabolism and which class of HDACs is mainly involved in the modulation of 
metabolic processes. Our previous work demonstrated that in a genetic model of 
©    2016 Macmillan Publishers Limited. All rights reserved.
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obesity and insulin resistance such as the db/db mouse, the class I selective HDAC 
inhibitor MS-275 enhanced oxidative metabolism in skeletal muscle and adipose 
tissue and promoted energy expenditure, leading to reduction of body weight and 
improvement of insulin sensitivity (15). Interestingly, MS-275 was able to induce a 
metabolic switch of white adipose tissue (WAT) toward a more oxidative phenotype 
resembling the features of brown adipose tissue (BAT), a phenomenon referred to as 
“browning”. Upon physiological stimuli such as chronic cold exposure (16), 
hormonal stimuli (e.g. irisin) (17), pharmacological treatment (thiazolidinediones) 
(18) or β-adrenergic stimulation (19), WAT switches the genetic program towards a 
brown-fat-like phenotype characterized by induced expression of uncoupling protein 
1 (Ucp1), cell death-inducing DFFA-like effector a (Cidea), and diodinase 2 (Dio2). 
These inducible or recruitable brown adipocytes, also known as “brite” (brown in 
white) or beige adipocytes, compared to classical brown adipocytes show lower 
number of mitochondria and thermogenesis capacity at basal state; however, upon 
appropriate external cues, they become multilocular and increase number of 
mitochondria, resembling BAT phenotype (20). This morphological change, together 
with inducible expression of UCP1 and other genes related to mitochondrial 
biogenesis, results in a cell type that participates to adaptive thermogenesis and 
energy expenditure similar to classical BAT. It has been shown that browning of 
WAT is an efficient strategy to counteract obesity and diabetes in rodent models (21, 
22). 
Genetic obesity and diet-induced obesity differ in term of lipid metabolism and 
adipose tissue phenotype (23). Epidemiological studies showed that dietary habits is 
an important determinant of body weight in humans and that a diet enriched in fat 
increases the incidence of obesity (24). Moreover leptin resistance in humans is rarely 
©    2016 Macmillan Publishers Limited. All rights reserved.
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related to a mutation in leptin gene; thus the use of murine models of obesity with 
dysfunctional leptin signaling (ob/ob or db/db mice) could limit the translational 
relevance of the studies since it is not completely representative of human pathologic 
condition (25). Therefore, a diet-induced model of obesity may provide a framework 
that mimics more closely overweight humans and may be useful to study the 
pharmacology of obesity.  
In order to evaluate whether biochemical inhibition of class I HDACs could be a 
promising strategy in the treatment of diet induced obesity, here we evaluated the 
effect of MS-275 in mice fed high fat diet. We found that this class I HDAC inhibitor 
reduced body weight and improved glucose tolerance. Interestingly, treatment with 
MS-275 increased thermogenic capacity and induced browning of both visceral and 
subcutaneous WAT. Our work demonstrated the crucial importance of class I HDACs 
in the pathophysiology of obesity, unraveling the role of these enzymes in the 
determination of metabolic signature of WAT.  
 
MATERIALS AND METHODS 
 
Animal studies 
For high fat diet feeding experiment, C57BL/6J male mice were purchased from The 
Jackson Laboratory. Six-week-old male mice were fed high fat diet (HFD, 60% 
calories from fat, Research Diet, D12492) for 17 weeks, monitoring body weight and 
fasting glycaemia. At week 18, mice were randomized and treated for 22 days every 
other day with intraperitoneal injection of vehicle (DMSO) or MS-275 (10mg/kg). At 
the end of treatments, brown and white adipose tissues (inguinal subcutaneous and 
mesenteric visceral fat pads), liver and blood samples were collected from individual 
©    2016 Macmillan Publishers Limited. All rights reserved.
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animals. For blood analysis, HFD fed mice were fasted for 16 hours and blood was 
collected from the tail vein. Glucose levels were determined using One touch Ultra
®
 
glucometer. Triglyceride and cholesterol levels were determined by Plasma 
Triglyceride Kit (Sentinel) and by Plasma Cholesterol Kit (Sentinel). Non-esterified 
fatty acids (NEFA) levels were determined by NEFA Kit (Wako Diagnostics). Insulin 
levels were determined using AlphaLISA
®
 Human Insulin Research Immunoassay Kit 
(Perkin Elmer). Adiponectin and Leptin levels were determined using ELISA assay 
Kits (Genway). For glucose and insulin tolerance test, mice were fasted for 16 hours, 
and glucose levels from tail vein blood were determined before and 30, 60, 90, and 
120 min after i.p. injection of glucose (2 g/kg). For cold challenge test, basal rectal 
temperature was measured at 24°C. Subsequently, mice were housed for 140 minutes 
at 4°C and rectal temperature was measured every 20 minutes. 
All experiments were conducted in accordance with Italian regulations (decree no. 
116, 27 January 1992). 
 
Histological analysis of adipose tissues 
Brown adipose tissue, subcutaneous white adipose tissue, and liver were fixed with 
Carnoy solution (6 parts 100% ethanol, 3 parts chloroform, 1 part glacial acetic acid) 
for 24 hours at 4°C. Tissues were then transferred to 100% ethanol. Tissues were 
embedded in paraffin and 8μm sections were stained with hematoxylin and eosin. 
Images were taken at 20X magnification. Cell size of adipocytes from white adipose 
tissue sections were quantitated using Photoshop CS6 (Adobe Systems Inc., San Jose, 
California). 
 
Gene expression 
©    2016 Macmillan Publishers Limited. All rights reserved.
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RNA from adipose tissues was isolated using Qiazol Reagent
®
 (Qiagen), purified with 
commercial kit (RNeasy Lipid Tissue Mini kit, Qiagen), and quantitated with 
Nanodrop (Thermo Scientific, Wilmington, DE). Specific mRNA was amplified and 
quantitated by real time qPCR, using iScriptTM One Step RT PCR for Probes (Bio-
Rad Laboratories), following the manufacturer’s instructions. Data were normalized 
to 36B4 mRNA and quantitated setting up a standard curve.  
Each sample was run in triplicate using 36B4 as reference gene. Primers and probes 
were obtained from Eurofins MWG Operon and are available upon request. 
 
Protein analysis 
Adipose tissues were lysed with 2X SDS sample buffer (20% glycerol, 4% SDS, 100 
mM Tris-HCl pH 6.8, 100 mM dithiothreitol, 0.002% bromophenol blue), 1mM 
protease inhibitors (Sigma), and homogenized with TissueLyser (Qiagen). Tissue 
lysates were separated by SDS-PAGE, transferred onto nitrocellulose membranes, and 
sample loading and transfer were evaluated by Ponceau staining. Membranes were 
then blocked in 5% non-fat dry milk in 1X TBS. The following primary antibodies 
were used:  PPAR (1:500, sc-7273, Santa Cruz), UCP1 (1:1000, ab10983, Abcam). 
HRP-conjugated goat anti-mouse (Sigma-Aldrich) and goat anti-rabbit (Cell 
Signaling) secondary antibodies were used for detection with chemiluminescence 
(ECL, Pierce). 
 
Immunohistochemistry 
Sections of WAT and BAT (8 µm) were deparaffinized and antigen retrieval was 
performed with 0.05 M NH4Cl for 30 min at room temperature. Endogenous 
peroxidase activity was blocked with 1% H2O2 for 20 min. Blocking was performed 
©    2016 Macmillan Publishers Limited. All rights reserved.
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in 1% BSA–0.1% Triton X-100 for 1 h. Anti-UCP1 (Abcam) was applied (1:300) 
overnight at 4°C, followed by incubation with biotinylated secondary antibodies 
(1:3000). Histochemical reactions were performed using diaminobenzidine. 
Quantification of histochemical analysis was performed counting the number of 
pixels in gray scale intervals, using the software ImageJ. Color channels were split 
and the analysis was performed on green channel. The software generates the list of 
gray scale intervals (0-255) and the number of pixels in each interval. 
 
Magnetic resonance imaging 
At day 18 of treatment, mice were anesthetized and analyzed in a 4.7 Tesla Avance II 
magnetic resonance imaging (MRI) scanner (Bruker Corporation). After a gradient-
echo scout, 16 axial 1-mm-thick T1-weighted slices were placed in the abdominal 
region spanning from kidneys to bladder inclusive. The field of view was 30 X 30 
mm2 with a matrix of 128 X 128 pixels. Four averages of a spin echo sequence with 
echo time to 10 ms and repetition time 400 ms were acquired in 3’25”. The slice 
immediately frontal with respect to the ilium bone was chosen for visceral fat 
estimation and was computed as follows: (fat area)/(slice area). Areas were measured 
with Photoshop (Adobe Systems). 
 
Mass spectrometry analysis of hepatic fatty acids 
Livers from HFD fed obese mice treated with vehicle or with MS-275 were 
homogenized in methanol with tissue lyser (Qiagen). For quantitative analysis of fatty 
acids, aliquots of methanolic extracts after addition of internal standards 
(heneicosanoic acid, C21:0, and 
13
C-labeled linoleic acid, Sigma-Aldrich) were 
subjected to acid hydrolysis and processed as previously described (26). Fatty acid 
©    2016 Macmillan Publishers Limited. All rights reserved.
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quantification was performed on an API-4000 triple quadrupole mass spectrometer 
(AB SCIEX) coupled with a HPLC system (Agilent) and CTC PAL HTS autosampler 
(PAL System). 
 
Human adipose stromal cells (hASC) 
Cells were plated at a density of 10
5
 cell/ml and differentiated for 4 days in presence 
of 50M insulin, 100nM dexamethasone, 0.25mM isobutylmethylxantine (Sigma 
Aldrich), 100nM rosiglitazone (Cayman Chemical). Then medium was refreshed 
every other day from day 4 to day 10 of differentiation with of 50M insulin, 100nM 
dexamethasone (Sigma Aldrich), 100nM rosiglitazone (Cayman Chemical). At the 
end of differentiation cells were treated for 48 hours with DMSO or with 1M MS-
275. 
 
Statistical analyses 
Statistical analyses were performed using the unpaired two-tailed Student t test with 
GraphPad PRISM (San Diego, CA). 
 
RESULTS 
 
Inhibition of class I HDACs improves obese phenotype and reduces adiposity 
To investigate whether inhibition of class I HDACs could counteract obesity and 
insulin resistance in a mouse model of diet-induced obesity (DIO mice), we fed 6-
week-old male C57BL/6J mice with high fed diet (HFD, 60% kcal from fat). After 17 
weeks on HFD mice were randomized in two groups, without statistically significant 
difference in weight and fasting glycaemia. Mice were treated for 22 days, every other 
©    2016 Macmillan Publishers Limited. All rights reserved.
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day, with vehicle DMSO or with the class I selective HDAC inhibitor MS-275 
10mg/kg (Figure 1A), as previously reported (15). Starting from day 16 of treatment, 
MS-275 treated mice showed a lower body weight (Figure 1B), yielding 10% 
reduction at day 22, with no statistically significant change in daily food intake 
(Supplementary Figure 1A). Body weight of each mouse before and after the 
treatments was reported in Table 1. MS-275 decreased the percentage of total WAT 
(Figure 1C, Supplementary Figure 1E) and in particular MRI analysis showed 
statistical significant reduction of subcutaneous WAT (Supplementary Figure 1B) and 
a mild but not statistically significant decrease of visceral WAT (Supplementary 
Figure 1C). No difference of brown adipose tissue (BAT) mass was detected in mice 
treated with MS-275 (Supplementary Figure 1D). Glucose tolerance test showed that 
treatment with MS-275 improved glucose clearance in diet induced obese mice 
(Figure 1D), while insulin tolerance test showed no differences between the two 
groups (Supplementary Figure 1J). MS-275 was also able to improve leptin resistance 
as assessed by reduced levels of circulating leptin and by the increased expression of 
hypothalamic leptin receptor (Supplementary Figure 1F, 1G), while it had no effect 
on circulating levels of insulin and adiponectin (Supplementary Figure 1H, 1I). 
Hematoxylin and eosin staining of subcutaneous (inguinal) and visceral (mesenteric) 
WAT revealed that adipocytes were smaller in MS-275-treated mice (Figure 1E). 
 
MS-275 increased expression of markers of lipid catabolism and adipose functionality 
To explain the phenotypic effects observed in MS-275 treated mice we analyzed the 
gene expression profile in their adipose tissue depots. Interestingly, we found that 
MS-275 increased expression of the master regulator of adipogenesis Pparg and of 
other typical markers of adipose tissue functionality (Fabp4, Adipoq, Glut4, Plin) 
©    2016 Macmillan Publishers Limited. All rights reserved.
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(Figure 2A, 2B). The augmented expression of most of these genes (except Glut4) 
was statistically significant in the visceral WAT whereas, in spite of the general trend, 
only Glut4 and Plin resulted significantly enhanced in subcutaneous WAT. Of note, 
western blot analysis of subcutaneous WAT revealed strong increase in PPARγ 
protein expression (Figure 2C, Supplementary Figure 1K), suggesting a post-
transcriptional modulation of this protein in response to class I HDAC inhibition. We 
also found that class I HDAC inhibitor increased the expression of genes involved in 
lipolysis (Atgl) and fatty acid -oxidation (Cpt1b, Acadl) in both subcutaneous 
(Figure 2D) and visceral (Figure 2E) WAT. We hypothesized that the reduced lipid 
content in white adipocytes is the result of a higher catabolism, and that it is not 
related to an inefficient storage of lipids in WAT. In line with this observation, we did 
not detect an increase in circulating levels of triglycerides (Supplementary Figure 2A) 
and cholesterol (Supplementary Figure 2B). Measurement of NEFA revealed mild, 
though not statistically significant, increase in MS-275 group (Figure 2F). Moreover, 
we did not observe differences in the level of fatty acids in the liver of MS-275 
treated mice, as detected by hematoxylin and eosin staining (Supplementary Figure 
2C) and by mass spectrometry analysis (Supplementary Figure 2D), indicating that 
there is no ectopic lipid deposition in the liver in response to the HDAC inhibitor. To 
rule out the contribution of skeletal muscle to the metabolic profile in MS-275 treated 
mice, we analyzed expression of genes regulating metabolism in gastrocnemius 
(Supplementary Figure 2E) and found no changes in the expression of Ppargc1a, 
Pppargc1b and of cytochrome C (CytC). On the other hand, we detected increased 
expression of mitochondrial biogenesis genes Tfam and Tfb1m (Supplementary Figure 
2E). Interestingly gene encoding for the ETC protein COX7A1 was significantly 
reduced, suggesting no increase in oxidative potential upon MS-275 treatment in 
©    2016 Macmillan Publishers Limited. All rights reserved.
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skeletal muscle. Moreover, we found reduced expression of Glut4, indicating that 
amelioration of systemic glucose tolerance is not related to improved glucose uptake 
in skeletal muscle. 
 
Inhibition of class I HDACs increases thermogenic capacity 
Previous results in db/db mice demonstrated that class I HDAC inhibition increased 
heat production (15). Thus we investigated whether treatment with MS-275 could 
affect thermogenic capacity in diet induced obese mice. After acute exposure to 4°C 
MS-275 treated mice were able to better cope the cold challenge (Figure 3A). The 
organ most involved in the regulation of body temperature via non shivering 
thermogenesis is BAT (27). Magnetic resonance imaging of interscapular area 
revealed that BAT mass was not affected by MS-275 treatment (Supplementary 
Figure 1D). Hematoxylin and eosin staining in BAT from control and MS-275 treated 
mice showed that the HDAC inhibitor altered tissue morphology (Figure 3B, top 
panels), apparently reducing lipid accumulation, typically increased in BAT from 
obese mice. However, immunohistochemical analysis of UCP1 showed no differences 
in vehicle and MS-275 treated mice (Figure 3B, bottom panels). Accordingly, gene 
expression analysis did not show changes in the mRNA and protein expression of the 
key regulator of thermogenesis UCP1 (Figure 3C, 3D) and of the other genes 
typically expressed in brown fat (Adrb3, Cidea, Prdm16) (Figure 3C). Interestingly 
we detected an increased expression of typical BAT markers Dio2 and Elovl3. 
 
Inhibition of class I HDACs promotes lipid oxidation and browning in white fat 
Since we found increased heat production during cold exposure but we did not 
observe higher expression of UCP1 in BAT of mice treated with the class I HDAC 
©    2016 Macmillan Publishers Limited. All rights reserved.
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inhibitor, we wanted to explore whether MS-275 was able to induce a brown-like 
phenotype in WAT also in a model of diet induced obesity. Interestingly, mice treated 
with HDAC inhibitor showed clear signs of browning of both subcutaneous (Figure 
4A) and visceral WAT (Figure 4B), since Ucp1 and other genes typically expressed in 
BAT (Adrb3, Cidea, Dio2, Ppara) were upregulated. Immunohistochemical analysis 
of UCP1 confirmed its higher expression in subcutaneous (Figure 4C) and visceral fat 
(Figure 4D) of MS-275 treated mice. To deeply investigate the phenotypical 
rearrangement occurring upon class I HDAC inhibition in white adipose tissues we 
performed further gene expression analysis and we found upregulation of markers of 
fatty acid synthesis: fatty acid synthase (Fasn) was increased in both subcutaneous 
WAT and visceral WAT, while acetyl CoA carboxylase (Acaca) was significantly 
upregulated in visceral WAT (Supplementary Figure 3A, 3B). Moreover the gene 
expression analysis of inflammation markers revealed no differences in the mRNA of 
M1 markers iNOS and IL1 in adipose tissues (Supplementary Figure 3C, 3D), and a 
significant increase in subcutaneous WAT of markers of alternatively activated 
macrophages (M2) markers MRC1 and Cd163. We also measured levels of apoptosis 
markers (Caspases) but found no changes in MS-275 treated mice (Figure 
Supplementary Figure 3E, 3F), thus ruling out the contribution of apoptosis in white 
fat in body weight reduction. 
To extend our observations in murine models to the human settings, we treated 
differentiated human adipose stromal cells (hASC) with vehicle (DMSO) or with MS-
275 for 48 hours: we detected increased rate of differentiation in presence of class I 
HDAC inhibitor as assessed by Oil Red O staining (Supplementary Figure 3G, 3H). 
Although this preliminary observation suggests a possible role of class I HDACs in 
human adipose tissue physiology, further investigations will be required to assess 
©    2016 Macmillan Publishers Limited. All rights reserved.
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whether modulation of class I HDACs activity may reprogram adipocyte metabolism 
in humans. 
 
DISCUSSION 
Human obesity is often related to a diet enriched in fat and carbohydrates in Western 
countries (24). To provide new knowledge about metabolic disorders consequent to 
an unhealthy intake of calories from fat the most useful murine model is a diet-
induced model of obesity. It has in fact been shown that the use of genetic models of 
obesity with dysfunctional leptin signaling (ob/ob or db/db mice) could not be 
completely representative of human pathologic condition, considering that genetic 
mutations of leptin gene are rare in obese patients. Previous investigations showed 
that treatment of diet induced obese mice with HDAC inhibitor sodium butyrate 
improved insulin sensitivity by promoting energy metabolism in skeletal muscle and 
brown adipose tissue (10). However, the short chain fatty acid butyrate may display 
effects also through non-HDAC targets (e.g. FFAR2 and FFAR3) (13, 14). Therefore, 
in this study we decided to adopt a murine model of diet-induced obesity (DIO) to 
investigate the role of HDACs in this pathological condition, using the synthetic class 
I HDAC selective inhibitor MS-275. Here we reported that inhibition of class I 
HDACs by MS-275 reduces body weight and enhances glucose tolerance. The fact 
that treatment with MS-275 improved GTT but did not affect ITT could be ascribed to 
higher expression of Glut4 in adipose tissues resulting in amelioration of the capacity 
to handle glucose loads, rather than to increased insulin signaling and sensitivity. 
Moreover, class I HDAC inhibitor increased thermogenic capacity. This result 
prompted us to investigate further the effects of class I HDAC inhibitor in BAT. 
Although BAT mass did not change, we found that BAT morphology was improved 
©    2016 Macmillan Publishers Limited. All rights reserved.
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in MS-275 treated mice, which showed higher number of small multilocular brown 
adipocytes, expressing BAT markers such as Dio2 and Elovl3. Interestingly no 
significant changes were found in the expression of Ucp1 and Adrb3 thus arguing 
against increased heat production by BAT following MS-275 treatment. The two 
proteins encoded by these genes, uncoupling protein 1 and β3 adrenergic receptor, are 
in fact considered the key activators of the thermogenic program. However, we 
cannot completely exclude the contribution of BAT to increased thermogenesis in 
MS-275 treated mice since an important contribution of DIO2 to thermogenesis has 
been reported (28): Dio2-/- mice during cold exposure become hypothermic, despite 
normal expression of UCP1, demonstrating that type 2 iodothyronine deiodinase and 
uncoupling protein 1 regulate thermogenesis in a concerted fashion. Thus, we do not 
rule out that long-term exposure of MS-275 treated mice to cold could result in an 
increase of BAT uncoupling and functionality. However, an explanation for the 
increased thermogenic activation in response to acute cold exposure in MS-275 
treated mice came from the analysis of white fat. Our results indicate, in fact, that 
MS-275-elicited browning of WAT contributes in counteracting diet-induced obesity. 
As previously reported, browning of WAT occurring without changes of uncoupling 
protein 1 in BAT, is a successful strategy to counteract obesity (17), (29), (30). 
Interestingly, in both subcutaneous and visceral WAT from MS-275 treated mice we 
observed upregulation of Ucp1 and other markers of BAT. Thus “browning” of white 
adipose tissue consequent to inhibition of class I HDACs in DIO mice occurred both 
in subcutaneous and visceral WAT. Accordingly, expression of WAT functionality 
markers and of genes involved in triglycerides and fatty acid catabolism were 
upregulated in both types of white fat, though to a greater extent in visceral WAT. To 
date, browning of WAT has been obtained by pharmacological treatment or by 
©    2016 Macmillan Publishers Limited. All rights reserved.
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genetic manipulation (18, 20, 31) in inguinal WAT or in epidydimal WAT. Our data, 
showing browning in visceral mesenteric WAT, suggest that class I HDAC selective 
inhibition induces deep reprogramming of adipose phenotype, resulting in more 
functional visceral adipocytes. Recently, it has been demonstrated that leptin mediates 
white adipose tissue browning through sympathetic nerve activity on adipose tissue 
through proopiomelanocortin (POMC) neurons (32). Interestingly, leptin levels were 
reduced in MS-275 treated mice, thus we hypothesize that these mice are more 
sensitive to leptin. Gene expression analysis in hypothalamus seems to corroborate 
this interpretation, as leptin receptor mRNA levels were higher in mice treated with 
the HDAC inhibitor MS-275. Thus, based on our results (higher expression of leptin 
receptor leading to increased leptin sensitivity in hypothalamus in mice treated with 
MS-275) and on the published literature, it is possible that leptin plays a role in MS-
275-mediated browning of white adipose tissue. Gene expression analysis indicates 
that white adipocytes of MS-275 treated mice could catabolize triglycerides at higher 
rate as indicated by increased expression of adipose tissue lipase (Atgl). Typically, 
high lipolytic rate correlates with increased level of plasma NEFA, however, in our 
experimental settings circulating NEFA are not statistically different in two groups of 
mice. In MS-275 treated mice this is probably the result of enhanced fatty acid -
oxidation within WAT depots, that use fatty acids as a metabolic fuel, as proved by 
increased expression of β-oxidation genes (i.e. Ppara, Acadl, Cpt1b). Similarly to 
what happens to brown adipose tissue during cold exposure (33) and to white adipose 
tissue upon 3-adrenergic stimulation (34), MS-275 also boosted de novo fatty acid 
synthesis in subWAT and viscWAT, further confirming the browning effect mediated 
by class I HDAC inhibitor. We infer that activation of lipogenic program in brown-
like WAT might be an adaptive response to the increased requirement of fuel 
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molecules to feed the accelerated electron transport chain (ETC) flux due to 
uncoupling of ETC from oxidative phosphorylation. The finding of improved 
functionality of mesenteric white adipose tissue is particularly relevant when 
considering the link between the intra-abdominal fat accumulation typical of obesity 
and other related severe complications, such as insulin resistance/type 2 diabetes and 
ultimately cardiovascular events. In spite of these considerations the MRI analysis 
revealed a significant reduction of adipose mass in subcutaneous WAT whereas in 
visceral WAT the trend did not reach statistical significance. This could depend on 
different features of viscWAT and subWAT: subcutaneous fat, which is less 
susceptible to inflammation (35), is characterized by larger adipocytes and higher 
plasticity as compared to visceral fat. MS-275 reduced the size of both subcutaneous 
and visceral adipocytes, however the effect was more pronounced in subWAT. This 
dramatic reduction of subcutaneous adipocytes hypertrophy can explain the reduced 
subWAT mass, as detected by MRI analysis. Conversely, gene expression analysis of 
functionality markers showed that MS-275 is more efficient in visceral fat: visceral 
adipocytes are smaller than subcutaneous adipocytes, yet visceral fat is more 
susceptible to inflammation because of the lower critical size adipocytes in this depot 
(35). Thus, even though the reduction in adipocyte size is not as evident as in 
subWAT, the decrease of adipocyte hypertrophy is sufficient to rescue adipocyte 
functionality, as assessed by gene expression analysis. On the contrary, subcutaneous 
adipocytes in obesity feature greater expandability that does not impair their 
functionality. For this reason, the effects of MS-275 on the expression of functionality 
markers are less pronounced in subWAT as compared to the effects observed in 
viscWAT. In both subcutaneous and visceral WAT, MS-275 has no effect on adipose 
tissue inflammation typically associated to obesity, as assessed by unaltered 
©    2016 Macmillan Publishers Limited. All rights reserved.
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expression of pro-inflammatory macrophage (M1) markers. However, in subWAT 
inhibition of class I HDAC is able to induce the expression of alternatively activated 
macrophages (M2). The increased expression of these markers further corroborate the 
browning phenotype, since it has been reported that M2 macrophages produce 
cathecolamines that sustain adaptive thermogenesis activation (36), driving the 
development of cold-induced beige fat in inguinal WAT (37). Furthermore, the 
unchanged expression level of Caspases in subWAT and viscWAT highlights that 
inhibition of class I HDAC does not promote adipocytes apoptosis. 
Assuming that HDAC inhibitors do not act on specific organs but exert ubiquitous 
effects, we cannot exclude that MS-275 affects metabolism and physiology of other 
organs. At this regard, we looked at skeletal muscle gene expression and found that in 
gastrocnemius treatment with MS-275 slightly increased the expression of 
mitochondrial biogenesis genes (Tfam, Tfb1m) but it decreased expression of insulin 
dependent glucose transporter Glut4. This result might indicate that amelioration of 
systemic glucose tolerance is probably not related to improved glucose utilization in 
skeletal muscle, but to ameliorated glucose clearance by adipose tissue. It should be 
noted that selective Glut4 overexpression in adipose tissue prevents glucose 
intolerance in mice fed high fat diet (38); consistently, in our experimental model 
MS-275 increased Glut4 expression in subcutaneous WAT, which is likely to 
contribute to improved glucose tolerance.  
Another organ that may contribute to glucose tolerance is liver. However, histological 
images and mass spectrometry analysis did not show significant difference in hepatic 
lipid levels between control and MS-275 treated mice. Therefore we tend to exclude 
that the liver may play a role in improving glucose clearance in our experimental 
model.  
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It has been reported that hepatic deletion of HDAC3 (39, 40) leads to lipid 
accumulation in the liver. However, although MS-275 targets both HDAC1 and 
HDAC3, we found no hepatic steatosis in the liver of DIO mice treated with this 
inhibitor. This difference may be ascribed to the effect of global versus local HDAC3 
inhibition: in obese and diabetic mice, systemic HDAC3 inhibition (i.e., MS-275 
treatment) increases oxidative metabolism and energy expenditure in other tissues 
such as adipose tissue, thus preventing hepatic lipid buildup.  
The preliminary observations in human differentiated adipocytes highlight the role of 
class I HDACs in the regulation of adipocyte differentiation and functions in the 
human settings. Further analyses will shed light whether these effects result in a 
metabolic switch of human white adipocytes and whether HDAC inhibition could be 
evaluated as a possible strategy in the treatment of metabolic disorders. 
In conclusion, our results demonstrate that inhibition of class I HDACs ameliorates 
obese and diabetic phenotype in a model of diet-induced obesity. This is a 
consequence of improved functionality of adipose tissue, preventing the excessive 
lipid accumulation that would impair adipocyte function and lead to insulin 
resistance. The role of class I histone deacetylases in adipose tissue patho-physiology 
could be further explored in the quest of new therapeutic avenues for obesity and 
T2D. 
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FIGURE LEGENDS 
 
Figure 1: Inhibition of class I HDACs ameliorates diet-induced obesity 
a) Experimental paradigm in C57BL/6J male mice  
b) Body weight during pharmacological treatment in obese mice treated with vehicle 
DMSO or with MS-275 (n=15 per group). 
c) MRI analysis of abdominal (subcutaneous and visceral) fat of obese mice treated 
with vehicle DMSO or with MS-275 (n=7 per group). 
d) Intra-peritoneal glucose tolerance test in obese mice treated with vehicle DMSO or 
with MS-275 (n=6 per group). 
e) Hematoxylin and eosin staining and adipocyte size calculation of subcutaneous and 
visceral WAT obese mice treated with vehicle DMSO or with MS-275 (n=5 per 
group). Scale bar is 100 m. 
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Data are presented as mean  SEM. Statistical analysis: Student’s t test, *p<0.05, 
***p<0.001.  
 
Figure 2: MS-275 increases expression of markers of lipid catabolism and adipose 
functionality in WAT 
a) Gene expression profile of markers of adipose functionality in subcutaneous WAT 
of obese mice treated with vehicle DMSO or with MS-275 (n=15 per group) 
b) Gene expression profile of markers of adipose functionality in visceral WAT of 
obese mice treated with vehicle DMSO or with MS-275 (n=8-10 per group) 
c) Western blot analysis of PPAR in subcutaneous WAT of obese mice treated with 
vehicle DMSO or with MS-275 (see also longer exposure in Supplementary Figure 
1I). 
d) Gene expression profile of markers of triglyceride catabolism and fatty acid -
oxidation in subcutaneous WAT of obese mice treated with vehicle DMSO or with 
MS-275 (n=15 per group) 
e) Gene expression profile of markers of triglyceride catabolism and fatty acid -
oxidation in visceral WAT of obese mice treated with vehicle DMSO or with MS-275  
f) Plasma NEFA levels in DIO mice treated with vehicle DMSO or with MS-275 
(n=15 per group). 
Data are presented as mean  SEM. Statistical analysis: Student’s t test, *p<0.05, 
**p<0.01, ***p<0.001.  
 
Figure 3: Class I HDAC inhibition promotes thermogenesis 
a) Body temperature of obese mice treated with vehicle DMSO or with MS-275 
exposed to 4°C for 140 minutes (n=7 per group). 
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b) Top panels: hematoxylin/eosin staining of BAT of obese mice treated with vehicle 
DMSO or with MS-275. Bottom panels: immunohistochemical analysis and of UCP1 
in BAT of obese mice treated with vehicle DMSO or with MS-275. Scale bar is 100 
m.  
c) Gene expression analysis of BAT markers in brown fat of obese mice treated with 
vehicle DMSO or with MS-275 (n=15 per group). 
d) Western blot analysis and quantification of UCP1 in BAT of obese mice treated 
with vehicle DMSO or with MS-275. 
Data are presented as mean  SEM. Statistical analysis: Student’s t test, *p<0.05, 
**p<0.01, ***p<0.001.  
 
Figure 4: MS-275 induces browning of subcutaneous and visceral WAT 
a) Gene expression analysis of BAT markers in subcutaneous WAT of obese mice 
treated with vehicle DMSO or with MS-275 (n=15 per group). 
b) Gene expression analysis of BAT markers in visceral WAT of obese mice treated 
with vehicle DMSO or with MS-275 (n=8-10 per group). 
c) Immunohistochemical analysis and quantification of UCP1 in subcutaneous WAT 
of obese mice treated with vehicle DMSO or with MS-275 (n=3 per group). Scale bar 
is 100 m. 
d) Immunohistochemical analysis and quantification of UCP1 in visceral WAT of 
obese mice treated with vehicle DMSO or with MS-275 (n=3 per group). Scale bar is 
100 m. 
Data are presented as mean  SEM. Statistical analysis: Student’s t test, *p<0.05, 
**p<0.01, ***p<0.001.  
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Table 1. Body weight of mice before and after treatment with vehicle or MS-275
BW before treatment BW after treatment Weight loss (gr) % of weight loss Average of BW loss (%)
39.32 38.57 0.75 1.9 7.8
35.09 30.02 5.07 14.4
37.21 35.85 1.36 3.7
46.15 44.55 1.6 3.5
39.55 36.64 2.91 7.4
36.12 34.39 1.73 4.8
39.74 33.6 6.14 15.5
40.9 39.05 1.85 4.5
35.67 31.86 3.81 10.7
34.36 33.02 1.34 3.9
45.04 42.56 2.48 5.5
47.94 43.02 4.92 10.3
43.23 37.54 5.69 13.2
41.05 37.43 3.62 8.8
38.27 35.04 3.23 8.4
35.36 33.15 2.21 6.3 15.5
43.7 38.82 4.88 11.2
41.07 29.56 11.51 28.0
39.16 34.45 4.71 12.0
39.83 31.84 7.99 20.1
40.68 35.22 5.46 13.4
43.75 38.41 5.34 12.2
33.7 28.82 4.88 14.5
41.07 37.58 3.49 8.5
41.37 34.22 7.15 17.3
38.54 33.98 4.56 11.8
52.76 46.18 6.58 12.5
40.35 31.92 8.43 20.9
36.23 29.26 6.97 19.2
43.76 33.22 10.54 24.1
Vehicle
MS-275
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